Category Archives: Generics

Why the US and pharmaceutical giants want a provision in India’s patent law revoked

Source: Scroll.in | May 02, 2018 India’s patent laws are under attack again. This time, too, the target is a provision not commonly found in patent laws elsewhere. This rule requires patent holders to disclose whether they are working their … Continue reading

Posted in Generics, Indian Patent Law, IPR, Patents | Leave a comment

Will the Trump tariffs on China raise drug prices for Americans?

by Ed Silverama, StatNews | April 4, 2018 Now that the Trump administration has proposed 25 percent tariffs on thousands of Chinese-made products, including raw ingredients for a slew of medicines, there are concerns that prices for these products may rise, … Continue reading

Posted in Drug prices, Generics, Uncategorized | Leave a comment

Novartis must end ‘bullying tactics’ over life-saving medicines, campaigners says

Global protests ahead of Novartis AGM in Switzerland tomorrow Call for new CEO to clean up company following scandals in Colombia and Greece Thursday 1 March 2018 – Swiss multinational Novartis today faced international calls from an alliance of health … Continue reading

Posted in Compulsory Licensing, Generics, Novartis Case, Uncategorized | Leave a comment

Health groups irked by Supreme Court order on vaccine PSUs; mull fresh petition

on behalf of the All India Drug Action Network (AIDAN) and co-petitioners 19 February 2018 Several health groups expressed their strong disappointment with the order of the Supreme Court (SC) of February 12, 2018, which refused to review or recall … Continue reading

Posted in Generics, Uncategorized | Leave a comment

Cancer Drug Price Rises 1, 400% With No Generic to Challenge It

By Peter Loftus, Wall Street Journal Since 2013, the price of a 40-year-old, off-patent cancer drug in the U.S. has risen 1,400%, putting the life-extending medicine out of reach for some patients. Introduced in 1976 to treat brain tumors and Hodgkin … Continue reading

Posted in Cancer, Drug prices, Generics, Price hikes, Uncategorized | Leave a comment

India to oppose anti-generics proposals at RCEP meet

Source: LiveMint India stands firm in opposing proposals that could hinder global access to affordable generic drugs and life-saving vaccines South Korea and Japan have been pushing for proposals to extend drug and vaccine patent terms, a move that is … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

Global access to affordable medicines should not be restricted

MSF has witnessed the negative impact of monopoly pricing on life-saving medicines and vaccines in its medical projects all over the world. Courtesy- ajp.com.au As 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) agreement meet this week in Incheon, … Continue reading

Posted in Data Exclusivity, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS&IP rights, Uncategorized, WTO | Leave a comment

India Will Not Cross Red Lines on Generic Drugs in RCEP, but Stay Vigilant, Say Officials

Source: The Wire Healthcare watchers are calling on India to resist the free trade agreement’s provisions which could compromise India’s ability to keep supplying cheaper generic drugs to the world. Hundreds of government officials and activists huddle separately in South … Continue reading

Posted in Data Exclusivity, Generics, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

HIV+ community stage protest to drop harmful provisions in RCEP; arrested & released

Hyderabad, 24 July 2017: About 30 HIV positive people were arrested at Hotel Novotel in Hitec City and taken to Narsingi police station as they raised slogans and took out a flash protest against the harmful provisions in the Regional Comprehensive … Continue reading

Posted in FTA, Generics, HIV/Aids, Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

Regional Comprehensive Economic Partnership: Boosting trade or extending monopolies for big pharma?

Published: The Huffington Post India By Leena Menghaney, Head—South Asia, Médecins Sans Frontières (MSF) Access Campaign. MÉDECINS SANS FRONTIÈRES (MSF) Officials from the 16 countries negotiating the Regional Comprehensive Economic Partnership (RCEP) trade deal—which includes the ten ASEAN member states, … Continue reading

Posted in Data Exclusivity, FTA, Generics, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment